Summary
Forty-three patients with chronic myeloid leukaemia have been treated with hydroxyurea in order to be subjected to leucopheresis for white celi transfusions. Hydroxyurea decreases leucocytosis when it is administered and the blood granulocyte number increases soon after the drug is stopped. The survival of the patients is not different from the survival of the patients treated with conventional chemotherapy (busulphan, mitobronitol) and it is superior to the survival of patients treated with external radiotherapy or with 2P. Haff of the patients were subjected to splenectomy during first remission for a phase II trial They were not randomized, but the distribution according to age was similar in the two groups. A slight difference appears in favour of splenectomy so far as survival is concerned, but there were three postoperative deaths out of 16 patients. We conclude that a 
Introduction
During the past 10 years a few malignant diseases of the haemopoietic and lymphatic systems have been the subject of considerable therapeutic advance. In two of them-acute lymphatic leukaemia ) and Hodgkin's disease (Mathe and Tubiana, 1973) -the possibility of a cure is nearing reality. On the other hand, the prognosis of chronic myeloid leukaemia (C.M.L.) seems to have changed very little. This is all the more disappointing as "myeloid" cells that proliferate at the beginning of the disease are very sensitive to radiotherapy (Bauer and Hartweg, 1962; H. Schoen and R. Bauer, personal communication) and to several drugs which have become available in the past two decades-namely busulphan (Bernard et al., 1955; Galton and Till, 1955), mitobronitol (Sellei and Eckhardt, 1963; Maths et al., 1964) , demecolcine (Moeschlin et al., 1954; Cattan et al., 1966) , piposulfan (N, N14bis-(3-methanesulfonoxypropanoyl) piperazine) (Kenis, 1968) , and hydroxyurea (Fishbern et al., 1964; Cattan et al., 1966) . The explanation for this lack of progress appears to be the inevitable occurrence of a blastic proliferation ("blastic crisis") in patients who do not die from therapeutic or other medical accidents. This means that C.M.L. can be considered as the forerunner of an acute leukaemia. This concept underlies the strategy of the current E.O.R.T.C. "leukemia and hematosarcoma" group C.M.L. therapy protocol, which is designed to test the value of prophylactic antiblastic treatment.
The main object of this study was to settle a logistic and ethical problem which arose when Freireich et al. (1964) and our group (Schwarzenberg et al., 1965) showed that C.M.L. white cell transfusates contain physiologically active leucocytes that can cure agranulocytosis. The question then arose, Does leucopheresis harm patients with C.M.L.? The only way to get enough C.M.L. cells for transfusion in an active medical oncology service is to treat C.M.L. with hydroxyurea so that a high circulating leucocyte count develops when the course is interrupted. Hence it was important to find out whether a protocol combining hydroxyurea and leucopheresis does any harm to the patient and whether it is less effective than conventional radiotherapy or busulphan treatment.
The second object was to conduct at the same time a phase I trial on the effect of splenectomy. As it is known that splenectomy when performed during an active phase of the disease is very often complicated by thrombocytosis (P. Chevallier, personal communication) we proposed to do the splenectomy at the beginning of the first remission.
Methods and Patients
The following protocol was used. (a) The first and subsequent active phases of the disease were treated with hydroxyurea at a dose of 1,500-2,500 mg/day for adults until apparent remission, and then 500 mg/day as a maintenance dose. (b) When it was known that the patient's white cells would be needed as donor cells maintenance treatment was stopped one month beforehand in order for the peripheral blood leucocyte count to rise to 60,000/mm3. The patients (whose consent was obtained after the basis of the treatment had been explained to them) were then subjected to a series of leucophereses (fewer than 1011 cells). (c) Splenectomy was performed during the first remission, provided that there were no contraindications and the patients and their general practitioners agreed to this procedure.
Forty-three patients (22 (Mathe et al., 1964) , demecolcine (Cattan et al., (1966) , and piposulfan (unpublished data) table II. In 39 cases an "incomplete" remission was obtained, defined as a discrete leucocytosis with a few immature granulocytes still present in the blood. In seven cases the marrow was still a little more hyperplastic than normal on cytological examination, and in five the spleen was still palpable. The Ph1 chromosome was detected by bone marrow culture in all cases. A state of almost complete remission can be maintained for many months if hydroxyurea is given permanently at a dose needed to keep the patient symptom-free, as was observed in the patients who were not subjected to leucopheresis.
LEUCOPHERESIS IN HYDROXYUREA-TREATED PATIENTS
In the 36 patients who had repeated leucopheresis the leucocytosis and myelaemia were cyclic, relating to the administration of the drug; administration was deliberately stopped when the white cells were needed for transfusion. Examples of such cyclic behaviour of leucocytosis are shown in figs. 1 and 2. During such a cycle the patients were subjected to 5 to 60 leucophereses, at each of which between 910 and 10l granulocytes were removed. The very slight, non-therapeutic effect of leucopheresis on the blood leucocytosis is shown in fig. 3 .
The arguments for and against the use of a protocol which allows C.M.L. to relapse for the convenience of the physician must be evaluated. The cumulative duration of survival of patients submitted to the hydroxyurea-leucopheresis protocol was no different from the survival times of patients treated conventionally with busulphan (Haut et al., 1961; Medical Research Council, 1968) and mitobronitol (Co-operative Study Group, 1972) , which were only slightly longer than those obtained by irradiation of the spleen (Medical Research Council, 1968) and therapy with "P (Reinhard et al., 1959) , the latter survival time being no different from ithat of untreated patients (Minot et al., 1924) .
The median survival time in the present series was 39-6 months, while in the conventional busulphan chemotherapy trials it was about 40 months ( fig. 4 ). In conclusion, this protocol, which allows us to use C.M.L. patients with agranulocytosis complicated by septicaemia, works as well as con- ventional treatment, which deprives the haemato-oncological intensive care units of the best source of leucocytes for granulocyte transfusions. The findings presented here are limited to patients treated in specialized centres, and the toxicity problems in these centres seem to be identical, as is shown in table IV. We believe that these results favour the use of hydroxyurea compared with other forms of therapy when all patients treated in all centres are considered. During the past few years we have received in our haemato-oncological intensive care unit five patients with busulphan aplasia; three of them died. In our experience treatment of C.M.L. with busulphan is at present the most frequent cause of death from irreversible marrow aplasia. Amenorrhoea, melanoderma, pulmonary centre fibrosis Treated in other 3 2 Long-term aplasias in one year hospitals * The drug had to be administered at a higher dose and for a prolonged period because of severe splenomegaly.
SPLENECTOMY
Of the 43 patients 18 were splenectomized during their first remission and 25 (or their doctors) refused this operation. The age distributions of the two groups of patients were very similar ( fig. 5) . The cumulative duration of survival was a little longer in the splenectomy group (median 43 months, mean 51 months) than in the non-splenectomy group (median 37 months, mean 37-1 months), but one must take into account three postoperative deaths due to hospital infections, and in two cases the spleen was infiltrated with blast cells (fig. 6 ). So far as other complications of splenectomy are con-, Splenectomized
Not splenectomized -,, show that there were no differences in the development of blastic crises or in the frequency of remissions but that there was a slight difference in survival from the onset of blastic crisis.
Introduction
Estimates of the incidence of coeliac disease vary considerably. In 1950 Davidson and Fountain estimated the incidence to be about 1 in 8,000 in England and Wales and 1 in 4,000 in Scotland. Carter et al. (1959) , in London, found an incidence of between 1 in 2,000 and 1 in 6,000, and McCrae (1969) calculated the incidence at 1 in 1,850 in Edinburgh. We report a much higher incidence in the West of Ireland.
Site of Study The Regional Hospital, Galway, is the teaching hospital for University College, Galway. It is a 700-bed general hospital with a 50-bed paediatric unit. The paediatric unit has had a special interest in coeliac disease since its establishment in 1956. In 1969 a gastrointestinal unit was opened and, from this, knowledge of the occurrence of coeliac disease in adults was
